PDGFRB and posterior cortical atrophy: However, a phase I clinical trial with a potent PDGFR inhibitor, imatinib mesylate in combination with docetaxel, in castration-resistant PCa patients with bone metastasis did not show any improvement in the median progression-free survival of patients, as compared to docetaxel alone (207).